Despite a bolus of IPOs hitting the road last week, buysiders don't think the uptick in meetings will be overwhelming. A combination of familiarity with the private companies and the quality of the names means specialist investors are able to give everyone a look.

Following this month's JPMorgan Healthcare Conference, Atlas Venture's Bruce Booth noted on his blog that